Abstract
Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Current Pharmaceutical Design
Title:GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Volume: 21 Issue: 34
Author(s): Carlos Alberto Yasin Wayhs, Helena Maria Tannhauser Barros and Carmen Regla Vargas
Affiliation:
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Abstract: Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Export Options
About this article
Cite this article as:
Wayhs Alberto Yasin Carlos, Barros Maria Tannhauser Helena and Vargas Regla Carmen, GABAergic Modulation in Diabetic Encephalopathy-Related Depression, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150914121331
DOI https://dx.doi.org/10.2174/1381612821666150914121331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Protein Tyrosine Phosphatases in Plants
Current Genomics Sudden Unexplained Death in Infancy and Long QT Syndrome
Current Pediatric Reviews The Anticonvulsant Effects of Ketogenic Diet on Epileptic Seizures and Potential Mechanisms
Current Neuropharmacology Graphical Abstracts
Letters in Drug Design & Discovery Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Investigating Serotonergic Function Using Positron Emission Tomography: Overview and Recent Findings
Current Pharmaceutical Design Population Pharmacokinetics of Levetiracetam: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells
Current Pharmaceutical Biotechnology Bhasma: Indian Perspective of Nanomedicinal Technology
Recent Patents on Nanomedicine HDACs and HDAC Inhibitors in Urothelial Carcinoma – Perspectives for an Antineoplastic Treatment
Current Medicinal Chemistry Nonsynaptic Receptors for GABA and Glutamate
Current Topics in Medicinal Chemistry The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance
Current Clinical Pharmacology Synthesis and Evaluation of Anticonvulsant Activities of Pyrazol yl Semicarbazones. Part II
Letters in Drug Design & Discovery A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives
CNS & Neurological Disorders - Drug Targets Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics Disorder in Milk Proteins: α-Lactalbumin. Part B. A Multifunctional Whey Protein Acting as an Oligomeric Molten Globular “Oil Container” in the Anti-Tumorigenic Drugs, Liprotides
Current Protein & Peptide Science The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Iptakalim Hydrochloride and Neuronal Protection
Current Neuropharmacology Nutraceuticals for Protection and Healing of Gastrointestinal Mucosa
Current Medicinal Chemistry